Volpara Health Technologies Limited (VPAHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Volpara Health Technologies Limited (VPAHF) trades at $0.74 with AI Score 60/100 (Grade B+). Volpara Health Technologies Limited develops AI-powered breast and lung imaging analytics software for healthcare providers globally. Market cap: $188.24M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for VPAHF: VPAHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VPAHF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VPAHF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Volpara Health Technologies Limited (VPAHF) Healthcare & Pipeline Overview
Volpara Health Technologies Limited specializes in AI-powered breast imaging analytics software, providing solutions like Volpara Analytics, Live, and Risk to optimize screening operations, assess image quality, and identify high-risk patients. Headquartered in New Zealand, the company serves healthcare providers globally, enhancing early detection and clinical decision-making in breast and lung cancer screening.
What Is the Investment Thesis for VPAHF?
Volpara Health Technologies Limited (VPAHF) operates in the growing medical imaging analytics market, leveraging AI to enhance breast and lung cancer screening efficiency and accuracy. The company's robust gross margin of 76.8% indicates strong unit economics for its software products. Key value drivers include the recurring revenue potential from its subscription-based software model and the increasing adoption of AI in healthcare for improved diagnostic precision. Growth catalysts are anticipated from the expansion of its global footprint across North America, Asia Pacific, Europe, the Middle East, and Africa, coupled with the continuous development of its AI-powered product suite, such as Volpara Science and its specialized clinical functions like TruDensity and TruPGMI. The strategic relationship with RevealDx also presents opportunities for market penetration and product integration. However, the company currently reports a profit margin of -28.0%, indicating ongoing investment in growth and operations, which poses a financial risk. The beta of 1.67 suggests higher volatility compared to the broader market. Sustained investment in R&D and market expansion will be critical for VPAHF to transition towards profitability and capitalize on its high gross margin.
Based on FMP financials and quantitative analysis
VPAHF Key Highlights
- Gross Margin of 76.8% demonstrates strong profitability on its software and services.
- Profit Margin of -28.0% indicates the company is currently operating at a loss, likely due to investments in growth and R&D.
- Market Capitalization stands at $0.19 billion, reflecting its current valuation as a small-cap healthcare technology firm.
- Beta of 1.67 suggests the stock is more volatile than the overall market, potentially appealing to investors with higher risk tolerance.
- Headquartered in Wellington, New Zealand, with a global operational footprint spanning North America, Asia Pacific, Europe, the Middle East, and Africa, indicating international market reach.
Who Are VPAHF's Competitors?
VPAHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| CMPD CompuMed, Inc. | $6.20 | +0.00% | $8.00M | 60 |
| ONVVF Oneview Healthcare PLC | $0.40 | +150.00% | $306.89M | 60 |
| SMFR Sema4 Holdings Corp. | $0.31 | +26.78% | $246.37M | 60 |
| OMDA Omada Health | $22.85 | +2.05% | $1.36B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VPAHF's Key Strengths?
- Proprietary AI-powered breast and lung imaging analytics software.
- High gross margin of 76.8% on its software products.
- Comprehensive product suite covering image quality, risk assessment, and patient management.
- Global operational presence across multiple continents.
What Are VPAHF's Weaknesses?
- Negative profit margin of -28.0%, indicating unprofitability.
- Reliance on a niche market (breast and lung cancer screening).
- Higher stock volatility with a beta of 1.67.
- Disclosure status on OTC market is 'Unknown,' potentially impacting investor confidence.
What Could Drive VPAHF Stock Higher?
- Continued global expansion of its AI-powered breast and lung imaging analytics software into new and existing markets.
- Further development and integration of its Volpara Science AI platform to enhance diagnostic accuracy and operational efficiency.
- Deepening of strategic partnerships, such as the relationship with RevealDx, to broaden market reach and product offerings.
- Increasing adoption of personalized medicine and risk-based screening protocols, driving demand for Volpara's risk assessment tools.
- Potential improvements in financial performance, specifically moving towards profitability, as investments in growth mature.
What Are the Key Risks for VPAHF?
- Negative return on equity (-17.6%) — the business is not currently generating profit on shareholder capital.
- Sustained unprofitability, as indicated by a -28.0% profit margin, requiring continued capital investment.
- Intense competition in the medical imaging analytics market from larger, more established healthcare technology companies.
- Regulatory changes and compliance challenges in the diverse global healthcare markets where it operates.
- Dependence on the adoption rates of AI in diagnostic imaging and the acceptance of its specific software solutions by healthcare providers.
- Risks associated with trading on the OTC market, including lower liquidity, wider bid-ask spreads, and limited public disclosure.
What Are the Growth Opportunities for VPAHF?
- Expansion into Lung Cancer Screening Market: Volpara Lung, a patient management software streamlining lung screening workflow, represents a significant growth opportunity. The global lung cancer screening market is projected to grow, driven by increasing awareness and screening recommendations for high-risk individuals. By leveraging its existing AI and software expertise from breast imaging, Volpara can penetrate this adjacent market. This expansion could tap into a new revenue stream, diversifying its product portfolio and reducing reliance on breast imaging alone. The timeline for this growth is ongoing, as lung screening programs continue to mature and expand globally, particularly in regions with high smoking rates or occupational exposure risks.
- Increased Adoption of AI in Diagnostic Imaging: The broader healthcare industry is rapidly adopting AI for enhanced diagnostic accuracy and operational efficiency. Volpara Science, the AI-based software powering its products, positions the company to capitalize on this trend. As healthcare systems seek to improve early detection rates and optimize resource allocation, sophisticated AI tools like Volpara's, which provide objective assessments of image quality, breast density, and patient risk, become increasingly valuable. This opportunity is ongoing, with market projections indicating substantial growth in AI-driven medical diagnostics over the next decade, as technology matures and regulatory frameworks adapt.
- Global Market Penetration and Geographic Expansion: Volpara currently operates in North America, Asia Pacific, Europe, the Middle East, and Africa. There is substantial opportunity for deeper penetration within these existing markets and expansion into new emerging markets. Many regions are still developing their breast and lung cancer screening infrastructure, presenting a greenfield opportunity for Volpara's software solutions. Strategic partnerships, similar to its relationship with RevealDx, can accelerate market entry and adoption. This growth driver is ongoing, with a long-term horizon as healthcare systems worldwide continue to modernize and invest in advanced diagnostic technologies.
- Enhancing Risk Assessment and Personalized Screening: Volpara Risk and Volpara Risk Pathways, which integrate with Patient Hub to calculate breast cancer risk using TC8 and manage high-risk patients, align with the growing trend towards personalized medicine. As understanding of genetic and lifestyle risk factors for cancer improves, healthcare providers are increasingly moving away from one-size-fits-all screening protocols. Volpara's tools enable more targeted screening, potentially leading to earlier detection in high-risk groups and reduced unnecessary procedures in low-risk individuals. This opportunity is ongoing, driven by clinical guideline updates and the demand for more precise, patient-centric care models.
- Leveraging Clinical Functions for Improved Image Quality: Volpara's clinical functions like TruPGMI (patient positioning and image quality), TruPressure (compression optimization), and TruRadDose (radiation dose analysis) address critical aspects of mammography quality and patient safety. Suboptimal image quality or excessive radiation can lead to missed diagnoses or patient discomfort. By providing objective, AI-driven feedback, these tools help clinics maintain high standards, reduce re-scans, and improve patient experience. As regulatory bodies and accreditation programs emphasize quality metrics, the demand for such tools is expected to rise. This is an ongoing growth opportunity, with a continuous need for quality assurance in diagnostic imaging.
What Opportunities Does VPAHF Have?
- Growing global demand for AI-driven diagnostic tools in healthcare.
- Expansion into new geographic markets and deeper penetration in existing ones.
- Diversification into adjacent diagnostic areas beyond breast and lung screening.
- Strategic partnerships to enhance market reach and product integration (e.g., RevealDx).
What Threats Does VPAHF Face?
- Intense competition from larger medical imaging companies and other software providers.
- Rapid technological advancements requiring continuous R&D investment.
- Regulatory changes and compliance requirements in global healthcare markets.
- Potential for data security breaches or privacy concerns with patient health information.
What Are VPAHF's Competitive Advantages?
- Proprietary AI-driven algorithms and software, such as Volpara Science, which powers its unique clinical functions like TruDensity and TruPGMI.
- Extensive dataset and clinical validation for its breast imaging analytics, contributing to accuracy and reliability.
- Global operational footprint and established presence in multiple key markets (North America, Europe, Asia Pacific).
- Integrated product suite that addresses multiple aspects of the screening workflow, from image quality to risk assessment and patient communication.
What Does VPAHF Do?
Volpara Health Technologies Limited, incorporated in 2009 and headquartered in Wellington, New Zealand, is a specialized provider of breast imaging analytics software solutions. The company's core mission revolves around leveraging artificial intelligence to enhance the quality and efficiency of breast cancer screening, ultimately aiming for earlier detection and improved patient outcomes. Volpara's product suite is comprehensive, addressing various facets of the screening workflow. Key offerings include Volpara Analytics, a software designed to optimize breast cancer screening operations by providing actionable insights. Volpara Live delivers instant, patient-based image quality feedback, crucial for ensuring diagnostic accuracy at the point of care. Beyond breast screening, the company also offers Volpara Lung, a patient management software that streamlines the workflow for lung screening programs. A significant component of Volpara's portfolio is the Volpara Patient Hub, a customizable mammography reporting and patient communications software that facilitates better engagement and information dissemination. Integrated with Patient Hub is Volpara Risk, which utilizes the TC8 model to calculate a patient's risk of developing breast cancer, enabling more personalized screening protocols. Complementing this is Volpara Risk Pathways, a program specifically designed for identifying and managing high-risk breast cancer screening patients. The Volpara Scorecard provides essential patient breast density and risk insights, supporting improved clinical decision-making. At the technological heart of these products is Volpara Science, an AI-based software platform that powers the entire Volpara ecosystem. The company's clinical functions, such as TruDensity, TruPGMI, TruPressure, and TruRadDose, further illustrate its commitment to precision. TruDensity objectively assesses breast density, a critical factor in cancer risk and screening efficacy. TruPGMI uses AI to automatically evaluate patient positioning and image quality, while TruPressure ensures optimal compression during mammography for quality images with minimal discomfort and radiation. TruRadDose analyzes radiation exposure based on breast density. Volpara Health Technologies operates on a global scale, with its solutions deployed across North America, the Asia Pacific, Europe, the Middle East, and Africa. The company also maintains a strategic relationship with RevealDx, further expanding its reach and capabilities in the diagnostic imaging space. This extensive product range and global presence underscore Volpara's evolution into a key player in healthcare information services, focused on advanced diagnostics.
What Products and Services Does VPAHF Offer?
- Develops AI-powered software for breast imaging analytics.
- Offers Volpara Analytics to optimize breast cancer screening operations.
- Provides Volpara Live for instant patient-based image quality feedback during screenings.
- Markets Volpara Lung, a patient management software for streamlining lung screening workflows.
- Delivers Volpara Patient Hub for customizable mammography reporting and patient communications.
- Integrates Volpara Risk with Patient Hub to calculate breast cancer risk using TC8.
- Offers clinical functions like TruDensity (breast density), TruPGMI (image quality), TruPressure (compression), and TruRadDose (radiation dose analysis).
- Operates globally across North America, Asia Pacific, Europe, the Middle East, and Africa.
How Does VPAHF Make Money?
- Generates revenue primarily through subscription-based software licenses for its analytics and patient management platforms.
- Provides ongoing support and maintenance services for its deployed software solutions.
- Monetizes its AI-powered clinical functions, such as TruDensity and TruPGMI, likely through bundled offerings or add-on modules.
- Engages in strategic partnerships, like with RevealDx, which may involve licensing agreements or joint ventures.
What Industry Does VPAHF Operate In?
Volpara Health Technologies Limited operates within the Medical - Healthcare Information Services industry, a segment experiencing significant growth driven by the digitalization of healthcare and the increasing adoption of artificial intelligence for diagnostics and operational efficiency. The broader market for medical imaging analytics is expanding as healthcare providers seek solutions to improve screening accuracy, reduce costs, and manage patient data more effectively. Volpara positions itself as a specialist in breast and lung imaging analytics, offering AI-powered software that enhances early cancer detection and streamlines clinical workflows. The competitive landscape includes larger medical imaging companies and specialized software providers. Volpara differentiates itself through its focus on specific clinical functions like breast density assessment (TruDensity) and image quality feedback (TruPGMI), aiming to capture market share by offering precise, AI-driven tools that integrate into existing screening programs globally. The trend towards personalized medicine and risk-based screening further underscores the relevance of Volpara's offerings.
Who Are VPAHF's Key Customers?
- Hospitals and healthcare systems offering breast and lung cancer screening services.
- Diagnostic imaging centers and radiology clinics.
- Breast cancer screening programs and research institutions.
- Medical professionals, including radiologists, radiographers, and oncologists.
ROE -18%Key Financial Metrics
Return on equity for Volpara Health Technologies Limited stands at -17.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.1%, the inverse of the P/E and a quick read on earnings relative to price.
Volpara Health Technologies Limited (VPAHF) Valuation Context
Valued at $188.24M, VPAHF is classified as a micro-cap stock. Relative to its peer group, VPAHF's quantitative score of 60/100 is roughly in line with the peer average of 66/100.
Company Profile
Volpara Health Technologies Limited operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Wellington, NZ. The company is led by CEO Teri Jo Thomas. VPAHF has traded publicly since 2018.
F-Score 4/9Financial Health
Volpara Health Technologies Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.85 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Volpara Health Technologies Limited revenue of about $53.4M for fiscal 2026, with EPS near $0.03.
VPAHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, signaling potential growth.
- Community sentiment has shifted positively as discussions around women's health technology gain traction.
- Volpara's innovative approach to breast cancer screening is resonating well with healthcare professionals and investors alike.
- Positive media coverage highlighting advancements in their technology has boosted market perception significantly.
Bear Case
- Some analysts express concerns over the scalability of Volpara's solutions in a competitive market.
- Recent discussions in the community reflect skepticism about the company's ability to achieve profitability in the near term.
- Regulatory challenges in the healthcare sector could pose risks to Volpara's growth trajectory.
- Market sentiment remains cautious due to broader economic uncertainties affecting healthcare investments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
VPAHF Latest News
No recent news available for VPAHF.
VPAHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VPAHF.
Price Targets
Wall Street price target analysis for VPAHF.
VPAHF MoonshotScore
What does this score mean?
The MoonshotScore rates VPAHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Teri Jo Thomas
Unknown
Teri Jo Thomas serves as the leader of Volpara Health Technologies Limited, overseeing a global team of 156 employees. Her role involves guiding the company's strategic direction in the specialized field of AI-powered breast and lung imaging analytics. While specific details regarding her educational background and prior career history are not provided in the source data, her position as the managing executive indicates a significant level of experience in corporate leadership and potentially within the healthcare technology sector. Her responsibilities encompass driving product innovation, market expansion, and operational efficiency for a company focused on enhancing early cancer detection and clinical workflows through advanced software solutions.
Track Record: Under Teri Jo Thomas's leadership, Volpara Health Technologies Limited continues to develop and deploy its suite of AI-powered breast and lung imaging analytics software products across North America, Asia Pacific, Europe, the Middle East, and Africa. Her tenure has seen the ongoing management of a company with a strong gross margin of 76.8%, indicating effective management of product costs. The strategic relationship with RevealDx also reflects a key initiative during her leadership, aiming to broaden the company's market reach and collaborative efforts in diagnostics.
VPAHF OTC Market Information
Volpara Health Technologies Limited trades on the OTC market under the "OTC Other" tier. This classification typically includes companies that do not meet the disclosure requirements for OTCQX or OTCQB, or those that choose not to provide financial information to OTC Markets Group. Unlike major exchanges such as NYSE or NASDAQ, which have stringent listing standards regarding financial health, corporate governance, and minimum share price, the OTC Other tier has fewer requirements. This can lead to less transparency and potentially higher risk for investors due to limited publicly available information. Investors should be aware that companies in this tier may not provide regular financial reports or audited statements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure due to "Unknown" disclosure status, hindering comprehensive investor analysis.
- Lower liquidity and wider bid-ask spreads compared to exchange-listed stocks, making trading more challenging.
- Increased potential for price volatility due to fewer regulatory oversight and less institutional interest.
- Difficulty in obtaining reliable and timely financial information for informed decision-making.
- Risk of delisting or further tier degradation if disclosure standards are not met or improved.
- Independently verify any available financial statements and corporate news releases, considering the "Unknown" disclosure status.
- Research the company's business operations and market position through third-party industry reports and news.
- Assess the management team's background and track record, especially given the limited public information.
- Evaluate the company's competitive landscape and intellectual property protection for its software.
- Understand the specific regulatory environment for healthcare technology in its operating regions.
- Analyze trading volume and bid-ask spreads to gauge potential liquidity challenges.
- Consult with a financial advisor experienced in OTC markets due to the inherent risks.
- Incorporated in 2009, indicating a sustained operational history.
- Headquartered in Wellington, New Zealand, with a physical presence.
- Operates globally across North America, Asia Pacific, Europe, the Middle East, and Africa, suggesting international business activity.
- Has a strategic relationship with RevealDx, indicating external validation and partnerships.
- Employs 156 individuals, demonstrating a substantive workforce.
Volpara Health Technologies Limited Healthcare Stock: Key Questions Answered
What specific problems does Volpara Health Technologies Limited's software solve in breast cancer screening?
Volpara Health Technologies Limited's software addresses several critical challenges in breast cancer screening. Its solutions optimize screening operations through Volpara Analytics, providing insights to improve workflow efficiency. Volpara Live offers real-time feedback on image quality, reducing the need for repeat scans and ensuring diagnostic accuracy. TruDensity objectively assesses breast density, a key risk factor, while Volpara Risk and Risk Pathways identify and manage high-risk patients, enabling personalized screening. Furthermore, TruPGMI and TruPressure enhance image quality and patient comfort, while TruRadDose monitors radiation exposure. These integrated tools aim to improve early detection rates, streamline clinical processes, and enhance patient care globally.
How does Volpara Health Technologies Limited leverage artificial intelligence in its product offerings?
Volpara Health Technologies Limited extensively leverages artificial intelligence (AI) as a core component of its product offerings, primarily through its Volpara Science platform. This AI underpins various clinical functions, such as TruDensity for objective breast density assessment and TruPGMI for automatically evaluating patient positioning and image quality. The AI capabilities enable instant, data-driven feedback and analysis, which helps optimize breast cancer screening operations (Volpara Analytics) and provides crucial insights for risk assessment (Volpara Risk). By automating and standardizing complex analyses, Volpara's AI aims to enhance diagnostic accuracy, improve workflow efficiency, and support more informed clinical decision-making for healthcare providers across its global footprint.
What are the implications of Volpara Health Technologies Limited trading on the OTC market, particularly the 'OTC Other' tier?
Trading on the "OTC Other" tier of the OTC market for Volpara Health Technologies Limited (VPAHF) carries several implications for investors. This tier typically signifies less stringent disclosure requirements compared to major exchanges or even higher OTC tiers, with the company's disclosure status explicitly listed as "Unknown." This can result in limited publicly available financial information, making comprehensive due diligence challenging. Furthermore, OTC stocks often experience lower trading volumes and wider bid-ask spreads, leading to reduced liquidity and potential difficulty in executing trades at desired prices. Investors should be aware of the increased volatility and reduced regulatory oversight associated with this market segment.
Given its negative profit margin, how does Volpara Health Technologies Limited plan to achieve profitability?
While Volpara Health Technologies Limited currently operates with a negative profit margin of -28.0%, its high gross margin of 76.8% suggests strong underlying unit economics for its software products. The path to profitability likely involves scaling its global operations and increasing customer adoption to leverage its fixed costs more efficiently. Continued investment in research and development, particularly for its AI-powered Volpara Science platform and new offerings like Volpara Lung, aims to expand its market reach and product diversification. As the company grows its recurring revenue base from subscription services across North America, Asia Pacific, Europe, the Middle East, and Africa, it seeks to achieve economies of scale and transition towards sustainable positive net income.
How does Volpara Health Technologies Limited's strategic relationship with RevealDx contribute to its business?
Volpara Health Technologies Limited's strategic relationship with RevealDx is designed to enhance its market position and expand its capabilities within the diagnostic imaging sector. While specific details of the collaboration are not provided, such partnerships typically involve joint development, co-marketing, or integration of technologies. For Volpara, this relationship could facilitate broader market access for its breast and lung imaging analytics software, potentially leveraging RevealDx's existing distribution channels or customer base. It may also lead to the integration of complementary technologies, strengthening Volpara's product suite and offering more comprehensive solutions to healthcare providers. This collaboration represents an opportunity to accelerate growth and innovation in a competitive landscape.
What are the key factors to evaluate for VPAHF?
Volpara Health Technologies Limited (VPAHF) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does VPAHF data refresh on this page?
VPAHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VPAHF's recent stock price performance?
Volpara Health Technologies Limited (VPAHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI-powered breast and lung imaging analytics software. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived strictly from the provided source data. No external information or speculation has been included.